332 related articles for article (PubMed ID: 12097421)
1. "Superhumanized" antibodies: reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: application to an anti-CD28.
Tan P; Mitchell DA; Buss TN; Holmes MA; Anasetti C; Foote J
J Immunol; 2002 Jul; 169(2):1119-25. PubMed ID: 12097421
[TBL] [Abstract][Full Text] [Related]
2. Grafting of "abbreviated" complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody.
De Pascalis R; Iwahashi M; Tamura M; Padlan EA; Gonzales NR; Santos AD; Giuliano M; Schuck P; Schlom J; Kashmiri SV
J Immunol; 2002 Sep; 169(6):3076-84. PubMed ID: 12218124
[TBL] [Abstract][Full Text] [Related]
3. Rapid and reliable cloning of antibody variable regions and generation of recombinant single chain antibody fragments.
Gilliland LK; Norris NA; Marquardt H; Tsu TT; Hayden MS; Neubauer MG; Yelton DE; Mittler RS; Ledbetter JA
Tissue Antigens; 1996 Jan; 47(1):1-20. PubMed ID: 8929708
[TBL] [Abstract][Full Text] [Related]
4. Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only.
Tamura M; Milenic DE; Iwahashi M; Padlan E; Schlom J; Kashmiri SV
J Immunol; 2000 Feb; 164(3):1432-41. PubMed ID: 10640759
[TBL] [Abstract][Full Text] [Related]
5. Mutation of a single conserved residue in VH complementarity-determining region 2 results in a severe Ig secretion defect.
Wiens GD; Lekkerkerker A; Veltman I; Rittenberg MB
J Immunol; 2001 Aug; 167(4):2179-86. PubMed ID: 11490003
[TBL] [Abstract][Full Text] [Related]
6. Design and Generation of Humanized Single-chain Fv Derived from Mouse Hybridoma for Potential Targeting Application.
Khantasup K; Chantima W; Sangma C; Poomputsa K; Dharakul T
Monoclon Antib Immunodiagn Immunother; 2015 Dec; 34(6):404-17. PubMed ID: 26683180
[TBL] [Abstract][Full Text] [Related]
7. Engineering a humanized bispecific F(ab')2 fragment for improved binding to T cells.
Rodrigues ML; Shalaby MR; Werther W; Presta L; Carter P
Int J Cancer Suppl; 1992; 7():45-50. PubMed ID: 1428403
[TBL] [Abstract][Full Text] [Related]
8. V region carbohydrate and antibody expression.
Gala FA; Morrison SL
J Immunol; 2004 May; 172(9):5489-94. PubMed ID: 15100290
[TBL] [Abstract][Full Text] [Related]
9. On the domain pairing in chimeric antibodies.
Teplyakov A; Obmolova G; Carton JM; Gao W; Zhao Y; Gilliland GL
Mol Immunol; 2010 Aug; 47(14):2422-6. PubMed ID: 20554002
[TBL] [Abstract][Full Text] [Related]
10. Use of human germline genes in a CDR homology-based approach to antibody humanization.
Hwang WY; Almagro JC; Buss TN; Tan P; Foote J
Methods; 2005 May; 36(1):35-42. PubMed ID: 15848073
[TBL] [Abstract][Full Text] [Related]
11. Humanization of a mouse anti-human IgE antibody: a potential therapeutic for IgE-mediated allergies.
Kolbinger F; Saldanha J; Hardman N; Bendig MM
Protein Eng; 1993 Nov; 6(8):971-80. PubMed ID: 8309946
[TBL] [Abstract][Full Text] [Related]
12. Analysis of IgE antibodies from a patient with atopic dermatitis: biased V gene usage and evidence for polyreactive IgE heavy chain complementarity-determining region 3.
Edwards MR; Brouwer W; Choi CH; Ruhno J; Ward RL; Collins AM
J Immunol; 2002 Jun; 168(12):6305-13. PubMed ID: 12055246
[TBL] [Abstract][Full Text] [Related]
13. Antibody humanization by redesign of complementarity-determining region residues proximate to the acceptor framework.
Hanf KJ; Arndt JW; Chen LL; Jarpe M; Boriack-Sjodin PA; Li Y; van Vlijmen HW; Pepinsky RB; Simon KJ; Lugovskoy A
Methods; 2014 Jan; 65(1):68-76. PubMed ID: 23816785
[TBL] [Abstract][Full Text] [Related]
14. Humanization of monoclonal antibodies by CDR grafting.
O'Brien S; Jones T
Methods Mol Biol; 2003; 207():81-100. PubMed ID: 12412469
[No Abstract] [Full Text] [Related]
15. Comparison of the three-dimensional structures of a humanized and a chimeric Fab of an anti-gamma-interferon antibody.
Fan ZC; Shan L; Goldsteen BZ; Guddat LW; Thakur A; Landolfi NF; Co MS; Vasquez M; Queen C; Ramsland PA; Edmundson AB
J Mol Recognit; 1999; 12(1):19-32. PubMed ID: 10398393
[TBL] [Abstract][Full Text] [Related]
16. SDR grafting of a murine antibody using multiple human germline templates to minimize its immunogenicity.
Gonzales NR; Padlan EA; De Pascalis R; Schuck P; Schlom J; Kashmiri SV
Mol Immunol; 2004 Jul; 41(9):863-72. PubMed ID: 15261458
[TBL] [Abstract][Full Text] [Related]
17. Production of high-affinity human monoclonal antibody fab fragments to the 19-kilodalton C-terminal merozoite surface protein 1 of Plasmodium falciparum.
Cheng XJ; Hayasaka H; Watanabe K; Tao YL; Liu JY; Tsukamoto H; Horii T; Tanabe K; Tachibana H
Infect Immun; 2007 Jul; 75(7):3614-20. PubMed ID: 17452466
[TBL] [Abstract][Full Text] [Related]
18. Identification of a universal VHH framework to graft non-canonical antigen-binding loops of camel single-domain antibodies.
Saerens D; Pellis M; Loris R; Pardon E; Dumoulin M; Matagne A; Wyns L; Muyldermans S; Conrath K
J Mol Biol; 2005 Sep; 352(3):597-607. PubMed ID: 16095608
[TBL] [Abstract][Full Text] [Related]
19. Bovine IgM antibodies with exceptionally long complementarity-determining region 3 of the heavy chain share unique structural properties conferring restricted VH + Vlambda pairings.
Saini SS; Farrugia W; Ramsland PA; Kaushik AK
Int Immunol; 2003 Jul; 15(7):845-53. PubMed ID: 12807823
[TBL] [Abstract][Full Text] [Related]
20. Rearrangement of the human heavy chain variable region gene V3-23 in transgenic mice generates antibodies reactive with a range of antigens on the basis of VHCDR3 and residues intrinsic to the heavy chain variable region.
Mageed RA; Harmer IJ; Wynn SL; Moyes SP; Maziak BB; Brüggemann M; MacKworth-Young CG
Clin Exp Immunol; 2001 Jan; 123(1):1-8. PubMed ID: 11167990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
